Opportunity Information: Apply for PAR 18 329
Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) is a Small Business Innovation Research (SBIR) grant opportunity from the National Institutes of Health (NIH) designed to push forward practical technologies that can track real-world daily functioning in people who are at risk for, or already living with, Alzheimer's disease or related dementias. The focus is on research and development of tools such as wearables, mobile-based systems, and other technology platforms (including software applications) that can collect continuous, real-time or near-real-time data. Rather than relying only on occasional clinic visits or self-reported questionnaires, the goal is to capture objective, ongoing measures that reflect how someone is functioning day to day, which can be especially valuable for detecting subtle changes over time.
The announcement emphasizes technologies that measure variables tied to activities of daily living and everyday function, which are often among the earliest and most meaningful indicators of cognitive decline. In practice, this could include passive or active monitoring of mobility and gait, sleep patterns, daily routines, navigation and wayfinding, medication adherence behaviors, communication patterns, or other measurable signals that reflect independence and cognitive health. The opportunity is aimed at building and validating technology that can generate usable, continuous data streams, potentially enabling earlier identification of decline, better monitoring of progression, and improved assessment of outcomes that matter to patients and caregivers.
This funding opportunity uses the SBIR R43/R44 mechanism, meaning it supports small businesses through the typical phased innovation pipeline. Phase I (R43) generally supports early feasibility and proof-of-concept work, while Phase II (R44) supports further development, refinement, and steps toward commercialization or broader deployment. Importantly, the FOA is labeled "Clinical Trial Not Allowed," which signals that applicants should not propose NIH-defined clinical trials under this specific announcement. Work can still involve human-centered development and testing activities, but proposals need to be structured to remain outside the NIH definition of a clinical trial for this FOA, which affects how studies are designed and described.
Eligibility is restricted to small businesses, consistent with SBIR rules, and there are clear limits related to foreign involvement. Non-U.S. entities (foreign institutions) are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible to apply. However, foreign components, as defined in the NIH Grants Policy Statement, may be allowed in some circumstances, meaning a U.S. small business might be able to include certain foreign elements if they meet NIH policy requirements and are appropriately justified.
From an administrative standpoint, this is a discretionary grant opportunity in the health funding area, listed under CFDA number 93.866, and it was originally posted with the funding opportunity number PAR 18 329. The original closing date shown is 2020-01-05, and the source data lists an award ceiling of $350,000. The listing also notes "ExpectedAwards" without a specified number, suggesting that the exact number of awards may depend on appropriations, application volume, and overall NIH priorities at the time of funding decisions.
Overall, the opportunity targets the development of scalable, real-world monitoring technologies that can translate behavioral and functional data into meaningful indicators of cognitive health and daily functioning in AD/ADRD populations. It is oriented toward innovation that can move beyond episodic measurement and toward continuous, objective assessment, while fitting the SBIR model of building commercially viable tools that can ultimately be deployed in home, community, or care settings.Apply for PAR 18 329
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R43/R44 Clinical Trial Not Allowed)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
- This funding opportunity was created on 2017-10-25.
- Applicants must submit their applications by 2020-01-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $350,000.00 in funding.
- Eligible applicants include: Small businesses.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or AD/ADRD (NIH SBIR)
1. What is this funding opportunity about?
This is an NIH Small Business Innovation Research (SBIR) funding opportunity focused on research and development of practical technologies that can detect, monitor, and assess real-world daily functioning in people who are at risk for, or already living with, Alzheimer's disease and/or Alzheimer's disease related dementias (AD/ADRD). The intent is to support tools that generate objective, ongoing measures of day-to-day function rather than relying mainly on occasional clinic visits or self-reported questionnaires.
2. Which agency is offering the grant?
The opportunity is offered by the National Institutes of Health (NIH).
3. What grant mechanism is being used?
The funding uses the SBIR R43/R44 mechanism. R43 generally aligns with Phase I (early feasibility and proof-of-concept) and R44 aligns with Phase II (further development, refinement, and movement toward commercialization or broader deployment).
4. Who is eligible to apply?
Eligibility is restricted to small businesses, consistent with SBIR rules.
5. Are non-U.S. organizations eligible to apply?
No. Non-U.S. entities (foreign institutions) are not eligible to apply under this opportunity.
6. Can a U.S. small business include a non-U.S. component?
Non-U.S. components of U.S. organizations are not eligible to apply. However, foreign components (as defined in the NIH Grants Policy Statement) may be allowed in some circumstances if they meet NIH policy requirements and are appropriately justified.
7. What types of technologies are encouraged?
The announcement emphasizes practical technology platforms that can collect continuous, real-time or near-real-time data. Examples mentioned include wearables, mobile-based systems, software applications, and other technology platforms capable of capturing ongoing measures of function in everyday settings.
8. What kinds of daily functions or variables should the technology measure?
The focus is on variables tied to activities of daily living and everyday function, including measures such as mobility and gait, sleep patterns, daily routines, navigation and wayfinding, medication adherence behaviors, communication patterns, and other measurable signals related to independence and cognitive health.
9. Why is continuous monitoring emphasized instead of occasional assessments?
The goal is to capture objective, ongoing measures that reflect how someone is functioning day to day. Continuous or near-continuous data streams can help detect subtle changes over time and provide information that may be missed by episodic clinic visits or questionnaires.
10. What population is this program trying to help?
The opportunity targets technologies for individuals experiencing cognitive decline, Alzheimer's disease, and/or Alzheimer's disease related dementias (AD/ADRD), including people at risk for these conditions and those already living with them.
11. What is the intended impact of the technologies developed under this FOA?
The intended impact is earlier identification of decline, better monitoring of progression, and improved assessment of outcomes that matter to patients and caregivers by translating real-world behavioral and functional data into meaningful indicators of cognitive health and daily functioning.
12. Is this opportunity limited to in-clinic use, or does it support real-world settings?
The opportunity is oriented toward real-world monitoring and scalable tools that can ultimately be deployed in home, community, or care settings, rather than only in clinic environments.
13. Are clinical trials allowed under this funding opportunity?
No. The funding opportunity is labeled "Clinical Trial Not Allowed," meaning applicants should not propose NIH-defined clinical trials under this specific announcement.
14. Can projects still involve human participants?
Yes. The description notes that work can involve human-centered development and testing activities, but proposals need to be structured to remain outside the NIH definition of a clinical trial for this FOA. This distinction affects how studies are designed and described.
15. What is the award ceiling listed for this opportunity?
The source listing shows an award ceiling of $350,000.
16. How many awards are expected?
The listing notes "ExpectedAwards" without specifying a number, suggesting the number of awards may depend on appropriations, application volume, and NIH priorities at the time of funding decisions.
17. What is the CFDA number associated with this opportunity?
The opportunity is listed under CFDA number 93.866.
18. What is the funding opportunity number (FOA number)?
The funding opportunity number referenced is PAR 18 329.
19. What is the original closing date shown in the listing?
The original closing date shown is 2020-01-05.
20. What type of grant is this categorized as?
It is described as a discretionary grant opportunity in the health funding area.
21. What distinguishes Phase I (R43) versus Phase II (R44) within this SBIR program?
Phase I (R43) generally supports early feasibility work and proof-of-concept development. Phase II (R44) generally supports further development and refinement and steps toward commercialization or broader deployment.
22. What kinds of data collection does NIH appear to be looking for here?
The emphasis is on continuous, real-time or near-real-time data collection that produces usable data streams reflecting everyday functioning. The aim is to generate objective measurements that can be tracked over time.
23. What problem is this FOA trying to address in AD/ADRD measurement?
The FOA seeks to move beyond episodic measurement and self-report by enabling objective assessment of daily functioning, which can be among the earliest and most meaningful indicators of cognitive decline.
24. What are examples of functional outcomes that may matter to patients and caregivers?
Based on the examples provided, outcomes related to independence and everyday ability may include changes in mobility, sleep, routine stability, navigation/wayfinding ability, medication adherence behaviors, and communication patterns.
25. Does the FOA emphasize commercialization?
Yes. As an SBIR opportunity, it follows a phased innovation pipeline and is oriented toward building commercially viable tools that can be deployed more broadly after development and validation.
Browse more opportunities from the same category: Health
Next opportunity: Safety and Outcome Measures of Pain Medications Used in Children and Pregnant Women (R03 Clinical Trial Optional)
Previous opportunity: Young Faculty Award (YFA)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 18 329
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 18 329) also looked into and applied for these:
| Funding Opportunity |
|---|
| Technology to Detect, Monitor and Assess Daily Functions in Individuals with Cognitive Decline, Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD) (R41/R42 Clinical Trial Not Allowed) Apply for PAR 18 326 Funding Number: PAR 18 326 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Immunity in the Elderly (R01) Clinical Trial Optional Apply for RFA AI 17 037 Funding Number: RFA AI 17 037 Agency: National Institutes of Health Category: Health Funding Amount: $300,000 |
| Enhancing Central Neural Control of Mobility in Aging (U01 Clinical Trial Optional) Apply for RFA AG 18 019 Funding Number: RFA AG 18 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single-Site Investigator-Initiated Clinical Trials (R61/R33 Clinical Trial Required) Apply for PAR 18 406 Funding Number: PAR 18 406 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Role of Peripheral Proteostasis on Brain Aging and Alzheimer's Disease (R01 Clinical Trial Not Allowed) Apply for RFA AG 18 020 Funding Number: RFA AG 18 020 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3) - Clinical Trial Required Apply for PAR 18 407 Funding Number: PAR 18 407 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Data Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative U24 Clinical Trial Required) Apply for PAR 18 410 Funding Number: PAR 18 410 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R21) - Clinical Trial Not Allowed Apply for PA 18 408 Funding Number: PA 18 408 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Research Grants Using the Resources from the Osteoarthritis Initiative (OAI) (R01) - Clinical Trial Not Allowed Apply for PA 18 409 Funding Number: PA 18 409 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research (K01) - (Clinical Trials Not Allowed) Apply for RFA HL 18 026 Funding Number: RFA HL 18 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Accelerating Program Achievements to Control the Epidemic (APACE) in South Africa Apply for 72067418RFA00001 Funding Number: 72067418RFA00001 Agency: South Africa USAID-Pretoria Category: Health Funding Amount: $600,000,000 |
| Clarifying the Relationship between Delirium and Alzheimers Disease and Related Dementias (R01 Clinical Trial Optional) Apply for PAR 18 029 Funding Number: PAR 18 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIBIB Biomedical Technology Resource Centers (P41 Clinical Trials Optional) Apply for PAR 18 205 Funding Number: PAR 18 205 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01 Clinical Trial Required) Apply for PAR 18 028 Funding Number: PAR 18 028 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Revision and Resubmission Program Project Applications (P01 Clinical Trial Optional) Apply for PAR 18 030 Funding Number: PAR 18 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Global Infectious Disease Research Administration Development Award for Low-and Middle-Income Country Institutions (G11-Clinical Trial Not Allowed) Apply for PAR 18 335 Funding Number: PAR 18 335 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Phenotypic and Functional Studies on FOXO3 Human Longevity Variants to Inform Potential Therapeutic Target Identification Research (R01 Clinical Trial Optional) Apply for PAR 18 026 Funding Number: PAR 18 026 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Complex Integrated Multi-Component Projects in Aging Research (U19 Clinical Trial Optional) Apply for PAR 18 296 Funding Number: PAR 18 296 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Program Project Applications (P01 Clinical Trial Optional) Apply for PAR 18 297 Funding Number: PAR 18 297 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| 93.067 Apply for CDC RFA GH13 1368A Funding Number: CDC RFA GH13 1368A Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 18 329", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.